INVO Fertility completes acquisition of Family Beginnings Clinic

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 19 2026

0mins

IVF+4.65%

Should l Buy IVF?

Source: Newsfilter

INVO Fertility Inc's stock surged by 17.93% in pre-market trading as it crossed above the 5-day SMA.

The company has successfully completed the acquisition of Family Beginnings Clinic for $760,000, a strategic move expected to enhance its network of fertility care centers. This acquisition is projected to improve patient service quality and accessibility, with Family Beginnings contributing approximately $1 million in revenue and $200,000 in net income for the nine months ending September 30, 2025. CEO Steve Shum highlighted the importance of this transaction in expanding INVO's geographic footprint and service capabilities.

This acquisition not only strengthens INVO's market position but also ensures continuity of care with existing leadership at Family Beginnings remaining in place, allowing for a seamless integration of resources and services.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy IVF?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on IVF

About IVF

INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

INVO Fertility Receives Nasdaq Compliance Notice

3 hours agoseekingalpha

Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing rules due to a delay in filing its annual report for the year ended December 31, 2025, although this notice does not have an immediate impact on its stock listing or trading.
Remediation Plan: The company has 60 days to submit a plan to regain compliance and is currently working to complete the filing, citing the need for additional time to review complex accounting matters, which could affect its future financial transparency.
Accounting Review: INVO Fertility noted that the complexity of accounting issues led to the delay in reporting, which may impact investor confidence in the company's financial health, potentially exerting downward pressure on its stock price.
Market Reaction: While the current notice has not directly affected stock trading, investors should monitor whether the company can successfully submit its compliance plan within the stipulated timeframe to avoid further market uncertainty.

INVO Fertility Announces 1-for-5 Reverse Stock Split

Mar 25 2026Newsfilter

Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.

INVO FERTILITY TO IMPLEMENT 1:5 REVERSE STOCK SPLIT STARTING MARCH 27, 2026, BEFORE MARKET OPENING

Mar 25 2026moomoo

Announcement of Stock Split: Invofertility has announced a 1:5 reverse stock split.
Effective Date: The reverse stock split will take effect on March 27, 2026, during pre-market trading.

INVO Fertility Integrates Time-Lapse Incubation Technology

Mar 05 2026Newsfilter

Technology Adoption: INVO Fertility has integrated time-lapse incubation technology at its Wisconsin clinic, aiming to enhance laboratory care quality and patient service, reflecting the company's commitment to modern reproductive treatments.
Significant Patient Benefits: Continuous embryo monitoring through time-lapse imaging provides detailed developmental insights, aiding embryologists in making informed clinical decisions, thereby improving embryo selection success rates and increasing patient engagement.
Consistency in Care: Patients can receive video records of their embryo's development without added complexity, which not only enhances their understanding of the process but also boosts their confidence in the treatment.
Strategic Investment Focus: The adoption of this technology underscores INVO Fertility's commitment to investing in advanced technologies, aiming to expand access to fertility care through ongoing innovation and strengthen its competitive position in the reproductive services market.